Prophase Labs Inc
NASDAQ:PRPH
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Prophase Labs Inc
Research & Development
Prophase Labs Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Prophase Labs Inc
NASDAQ:PRPH
|
Research & Development
-$594k
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
8%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$14.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-7%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.5B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-8%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$12.6B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
Prophase Labs Inc
Glance View
ProPhase Labs, Inc. is a medical science and technology company. The company is headquartered in New York City, New York and currently employs 129 full-time employees. The firm operates through two segments: diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services. The firm is also engaged in the development and marketing of dietary supplements under the TK Supplements brand. The Company’s TK Supplements product line includes Legendz XL, a male sexual enhancement and Triple Edge XL, an energy and stamina booster.
See Also
What is Prophase Labs Inc's Research & Development?
Research & Development
-594k
USD
Based on the financial report for Dec 31, 2024, Prophase Labs Inc's Research & Development amounts to -594k USD.
What is Prophase Labs Inc's Research & Development growth rate?
Research & Development CAGR 10Y
8%
Over the last year, the Research & Development growth was 58%. The average annual Research & Development growth rates for Prophase Labs Inc have been -6% over the past three years , -15% over the past five years , and 8% over the past ten years .
